RXRX
Recursion Pharmaceuticals Inc
3.90$
+5.1%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
Recursion Pharmaceuticals Inc (RXRX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 7.7 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.1 | 0.2 | 0.9 | 2.6 | 2.5 | 2.5 | 2.5 | 2.5 | 5.3 | 7.7 | 13 | 14 | 12 | 11 | 10 | 11 | 13 | 14 | 26 | 4.5 | 15 | 19 | 5.2 | 36 | 6.5 | 7.7 | 55 | |
| 13 | 13 | 17 | 21 | 24 | 30 | 33 | 2.6 | 7.8 | 14 | 15 | 11 | 12 | 9.4 | 11 | 9.9 | 11 | 9.2 | 12 | 13 | 22 | 20 | 30 | 27 | 12 | 11 | 80 | |
| -13 | -13 | 0.9 | 2.6 | 2.5 | 2.5 | 2.5 | 2.5 | -2.5 | -6.6 | -2.4 | 2.8 | -0.3 | 1.6 | -0.8 | 0.7 | 2.3 | 5.2 | 14 | -8.3 | -7.1 | -1.1 | -24 | 8.7 | -6.0 | -3.8 | -26 | |
| 13 | 13 | 17 | 21 | 24 | 30 | 33 | 48 | 32 | 38 | 41 | 44 | 47 | 55 | 70 | 69 | 68 | 74 | 75 | 98 | 130 | 129 | 121 | 83 | 88 | 90 | 382 | |
| 5.6 | 5.2 | 7.0 | 7.6 | 8.9 | 14 | 16 | 19 | 21 | 21 | 19 | 20 | 23 | 28 | 29 | 30 | 31 | 32 | 38 | 77 | 55 | 47 | 42 | 34 | 35 | 42 | 151 | |
| 18 | 18 | 23 | 28 | 33 | 43 | 49 | 67 | 53 | 60 | 60 | 64 | 70 | 83 | 99 | 100 | 99 | 106 | 112 | 175 | 184 | 175 | 148 | 117 | 122 | 131 | 518 | |
| -18 | -18 | -22 | -26 | -30 | -41 | -46 | -65 | -56 | -66 | -63 | -61 | -70 | -82 | -100 | -99 | -96 | -101 | -98 | -184 | -191 | -176 | -172 | -108 | -129 | -135 | -544 | |
| 0.3 | 0.4 | 0.4 | 0.2 | 0.2 | 2.5 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | 0.6 | 0.6 | 0.5 | 0.5 | 0.8 | 0.0 | 0.4 | 0.3 | 1.5 | |
| -18 | -19 | -24 | -26 | -31 | -43 | -47 | -65 | -56 | -66 | -60 | -57 | -65 | -77 | -93 | -97 | -92 | -98 | -96 | -179 | -203 | -172 | -162 | -108 | -122 | -131 | -523 | |
| 0.1 | 0.7 | 1.4 | -0.5 | 0.2 | 2.5 | 1.0 | 0.0 | 0.0 | 0.0 | -2.1 | 0.0 | -4.5 | -5.5 | 1.6 | -4.1 | -0.8 | -0.5 | 0.2 | 0.0 | -0.2 | – | 0.0 | 0.0 | -4.6 | 0.0 | -4.6 | |
| -18 | -19 | -24 | -26 | -31 | -43 | -47 | -65 | -56 | -66 | -60 | -57 | -65 | -77 | -93 | -93 | -91 | -98 | -96 | -179 | -202 | -172 | -162 | -108 | -118 | -131 | -519 | |
| -17 | -17 | -23 | -24 | -29 | -39 | -45 | -62 | -53 | -63 | -57 | -54 | -62 | -71 | -85 | -89 | -85 | -89 | -88 | -165 | -183 | -148 | -141 | -89 | -102 | -113 | -444 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.